世界の選択的エストロゲン受容体分解薬(SERD)市場(~2025):投与量・価格・臨床試験インサイト

◆英語タイトル:Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price and Clinical Trials Insight 2025
◆商品コード:KUIK21FB003
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2021年1月
◆ページ数:150
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD2,400 ⇒換算¥273,600見積依頼/購入/質問フォーム
Multi UserUSD4,200 ⇒換算¥478,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Kuick Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、世界の選択的エストロゲン受容体分解薬(SERD)市場について調査・分析を行い、イントロダクション、作用機序、併用療法、がん治療におけるSERDの役割、乳がんにおけるSERD、市場分析、市場動向、臨床試験の概要、臨床試験インサイト、ファスロデックス(フルベストラント)、可用性・価格分析、競争状況などを掲載しています。
・イントロダクション
・作用機序
・併用療法
・がん治療におけるSERDの役割
・乳がんにおけるSERD
・市場分析
・市場動向
・臨床試験の概要
・臨床試験インサイト
・ファスロデックス(フルベストラント)
・可用性・価格分析
・競争状況
【レポートの概要】

“Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price and Clinical Trials Insight 2025″ Report Highlights:

Global SERD Market Opportunity: > US$ 2 Billion By 2025
USA To dominate Global SERD Market
SERD In Clinical Trials: > 15 Drugs
Detailed Clinical insight on All Drugs in clinical Trials
Clinical Pipeline Insight by Company, Country, Indication and Patient Segment
Branded and Generic Drug Dosage, Price and Sales Insight
150 Page Report: Commercial and Clinical Opportunity Insight

The research report, “Selective Estrogen Receptor Degrader (SERDs) Market, Dosage, Price and Clinical Trials Insight 2025” provides detailed insight on clinical and non clinical parameters involved in the development and expansion of the global SERD market. In addition to it, the research report also describes the impact of novel drug launches on the other available therapies for breast cancer as well as growth rate of the specific drugs available under the therapy. Other than the market forecast, the research report also highlights the future trends and opportunities that will highly impact the use of expensive drugs for the treatment of breast cancer. Some of the areas that are highlighted in the research report involves the market fragmentation based on the real-world evidence of the therapy at clinical and pre-clinical level.

The global selective estrogen receptor degrader therapy market is witnessed to exceed by a double-digit CAGR rate over the next few years, which will positively impact the other commercially available therapies and cause a notable slowdown in their market growth rate. The major key drivers for the therapy market are estimated to be the US market as well as emerging markets upto some extent, which in the future years will also continue to be the major drivers for the market. The current research and development pipeline for the therapy market is growing at a splendid rate, and the success rate for the market are accelerating at historic level, thus resulting in more launches of potential candidates in the upcoming years. The future novel products approved under selective estrogen receptor degrader therapy market are believed to contribute a large net sales and revenue generation, as the market brand will grow at extensive rate.

The current market is observed to lift the share of the oncology sector to the global pharmaceutical market to new extent, which will continue to increase with time. In addition to it, the overall market at global level has also observed a large influx in the number of market players and government initiatives so that large number of patients could receive benefits from such selective cancer therapy. The highly advanced satisfactory applications and benefits received from the therapy is believed to expand the market to become one standard care for patients suffering from breast cancer.

As per the research conducted for Global selective estrogen receptor degrader therapy market, it is estimated that the therapy when compared with other commercially available therapies can provide maximum potential returns to the breast cancer patients in terms of healthcare benefits as well as to the investors and bio-pharmaceutical companies in terms of total sales and revenue generation. The market due to strong and robust clinical pipeline is also brewing up to become more independently and economically strong. It is observed for the market, that the long-term healthcare benefits available will push the researchers towards conducting more complex clinical research studies in order to generate more applications for the breast cancer patients.

【レポートの目次】

Introduction to Selective Estrogen Receptor Degraders (SERDs)
1.1 Overview
1.2 Evolution of SERDs

Selective Estrogen Receptor Degraders – Mechanism of Action

Selective Estrogen Receptor Inhibitors as Combinational Therapy
3.1 SERD with CDK 4/6 Inhibitors
3.2 SERD with PI3K Inhibitors
3.3 SERD with Aromatase Inhibitors
3.4 SERDs with mTOR Inhibitors

Role of SERDs in Cancer Treatment

Selective Estrogen Receptor Degraders in Breast Cancer
5.1 Impact of SERDs in Breast Cancer Treatment
5.2 Ongoing Research and Development
5.2.1 AZD 9833
5.2.2 Rintodestrant (G1T48)
5.2.3 ZN-c5
5.2.4 Elacestrant (RAD1901)
5.2.5 LSZ 102
5.2.6 OP-1250
5.2.7 LY3484356
5.2.8 GDC-9545 (RG6171)
5.2.9 SHR9549
5.2.10 AZD9496

Selective Estrogen Receptor Degrader Market Analysis
6.1 Current Market Scenario
6.2 Impact of COVID-19 on Selective Estrogen Receptor Degrader Market
6.3 Market Opportunity

Selective Estrogen Receptor Degrader – Market Trends
7.1 Zentalis Pharma Collaborated with Eli Lily to Evaluate the Combination of SERD
with CDK4/6 Inhibitors
7.2 Olema Oncology and Novartis Announces Clinical Collaboration to Evaluate SERD
as Combinational Therapy
7.3 New SERD Combinational Therapy Shows Promising Results against HR+/HER2
Negative Breast Cancer
7.4 Radius and Menarini Collaborates for Development and Commercialization of
Elacestrant
7.5 SERD Combination Can Target the Neurofibromatosis Gene for Treating Breast
Cancer

Selective Estrogen Receptor Degrader (SERD) Inhibitors Clinical Trials Overview
8.1 By Company
8.2 By Indication
8.3 By Patient Segment
8.4 By Phase

Selective Estrogen Receptor Degrader (SERD) Clinical Trials Insight
9.1 Preclinical
9.2 Phase-I
9.3 Phase-I/II
9.4 Phase-II
9.5 Phase-III

Marketed Selective Estrogen Receptor Degrader (SERD) Insight: Fulvestrant

Faslodex (Fulvastrant)- Commercially Available Selective Estrogen Receptor Inhibitor Drug
11.1 Approval and Patent Dispute
11.2 Pricing and Dosage Analysis
11.3 Sales Analysis
11.4 Faslodex – Reimbursement Scenario

Generic Fulvestrant – Availability and Price Analysis
12.1 Fulviglen
12.2 Fulvenat
12.3 Fulvetraz
12.4 Fuvesterol
12.5 Strantas
12.6 Celvestrant
12.7 Faslomax
12.8 Fasnorm

Competitive Landscape
13.1 AsteraZeneca
13.2 Eli Lilly
13.3 G1 Therapeutics
13.4 Novartis
13.5 Olema Oncology
13.6 Radius Therapeutics
13.7 Roche
13.8 Sage Therapeutics
13.9 Zeno Pharma
13.10 Zentalisv



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の選択的エストロゲン受容体分解薬(SERD)市場(~2025):投与量・価格・臨床試験インサイト]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆